Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

ALCON INC (ALC)

As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data

Report price $73.64 (close 2026-11-16); latest close $74.31 (2026-11-20), +0.9% since the report; figures re-marked at the latest close

Conclusion: PASS

Conviction low · base case none · downside -31% · upside +11%

At $73.64, Alcon is priced as if shrinkage is the baseline: the $35.89B market cap and $39.10B enterprise value equal 36.6x FY2025 net income of $980.0M and 3.76x FY2025 EV/Sales, while the reverse DCF requires -1.2% revenue a year for ten years at a 16.6% FCF margin against the +4.9% revenue growth actually delivered in FY2025. That gap is real but not decisive, so the call is PASS, a low-conviction call resting on the two priced cases. The downside is -30.4% to $51.25, from -10.0% earnings at a compressed P/E of 28.3x (today 36.6x). The upside is +12.0% to $82.48, from +12% earnings at today's P/E of 36.6x. There is no base case: no comparable peer multiple sets one and the company's own history gives none; a base at today's multiple is today's price by construction. The market already pays for contraction, but without a base case the asymmetry is insufficient for a higher-conviction stance.

Key numbers

  • Share price: $74.31
  • Market cap: $36.22B
  • Latest financial period: FY Dec 2025 to Dec 31, 2025
  • Revenue (FY Dec 2025): $10.40B
  • P/E (FY Dec 2025): 36.9x
  • FCF yield: 4.8%
  • Price / book: 1.64x
  • EV / FCF (FY Dec 2025): 22.8x
  • Revenue growth (latest fiscal year): +4.9%
  • ROIC (FY Dec 2025): 4.5%
  • WACC: 6.2%
  • Economic profit spread: -1.7 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    Alcon reports in USD as a Swiss-domiciled, NYSE/SIX-listed eye-care company spun off from Novartis in April 2019; the only business detail in the sources is two segments, Surgical and Vision Care, plus FY2025 constant-currency sales growth of +4% and +5% respectively and $1.7 billion of FY2025 free cash flow (a non-IFRS measure). Between the oldest annual report here (FY2020) and the newest (FY2025), revenue rose from $6.83B to $10.40B, operating income from -$482.0M to $1.36B and operating cash flow from $823.0M to $2.27B, but FY2025 operating income ($1.36B) and net income ($980M) were slightly below FY2024 ($1.41B and $1.02B) on higher revenue, and FY2025 was described as performance below expectations on tariffs, trade uncertainty and soft Surgical conditions. The sources do not break out segment revenue or profit in dollars, so unit economics cannot be shown.

  2. ✓ 2. Competitive advantage

    Alcon has scale and product/brand strength in surgical and vision care — FY2025 revenue $10.40B, gross profit $5.75B, operating income $1.36B and operating cash flow $2.27B — but the 20-F describes an intensely competitive industry with named rivals, price pressure and disruptive distribution entrants. Its advantage appears to rest on technology, product breadth, eye-care-professional relationships and service rather than a structural monopoly. The dollar record improved from FY2020 to FY2025, but FY2025 operating income and net income slipped from FY2024, and the sources give no margin percentages or ROIC.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 sales rose 5% to $2,717M and nine-month sales rose 7% to $8,184M; Q3 operating income was $381M (14.0% margin) but included $58M of tariff refunds, a $38M contingent-consideration charge and $36M of efficiency costs. The nine-month operating margin fell to 8.4% because Q2 2026 booked a $505M PowerVision impairment and related items, while Q3 net income was $260M, +10%. Nine-month operating cash flow was $1,689M, cash was $1,705M at Sep 30 2026, inventories rose $178M, and Alcon bought back $574M of treasury shares under a new $1.5B authorization.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ○ 9. Insider trading interpretation
  10. ○ 10. Earnings-call notes
  11. ✓ 11. Impression of the shareholder letter

    Filled; members read this box.

  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans